<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="discussion"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Urol Focus</journal-id><journal-id journal-id-type="iso-abbrev">Eur Urol Focus</journal-id><journal-title-group><journal-title>European Urology Focus</journal-title></journal-title-group><issn pub-type="epub">2405-4569</issn><publisher><publisher-name>Published by Elsevier B.V. on behalf of European Association of Urology.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7274606</article-id><article-id pub-id-type="publisher-id">S2405-4569(20)30154-1</article-id><article-id pub-id-type="doi">10.1016/j.euf.2020.05.019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Abrams-Downey</surname><given-names>Alexandra</given-names></name><email>alexandra.abrams-downey@mssm.edu</email><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Saabiye</surname><given-names>Joseph</given-names></name></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Vidaurrazaga</surname><given-names>Monica</given-names></name></contrib><aff id="aff0005">Icahn School of Medicine at Mount Sinai, Division of Infectious Diseases, New York, NY, USA</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author. Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside Hospital, 440 West 114th Street, New York, NY 10025,USA. Tel. +1 212 5232525, Fax: +1 212 5233931. (A. Abrams-Downey). <email>alexandra.abrams-downey@mssm.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>5</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>5</day><month>6</month><year>2020</year></pub-date><history><date date-type="accepted"><day>29</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Published by Elsevier B.V. on behalf of European Association of Urology.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0005">Currently there are no therapeutics approved by the US Food and Drug Administration (FDA) for the treatment of COVID-19. Traditionally, the development of novel therapeutics takes years, including rigorous randomized controlled trials (RCTs), the gold standard of clinical research. However, the urgency of the COVID-19 pandemic has led to widespread use of unproven treatments, supported largely by observational studies. As outlined in the National Institute of Allergy and Infectious Diseases strategic plan for COVID-19 research <xref rid="bib0005" ref-type="bibr">[1]</xref>, it is essential to identify promising candidates with activity against SARS-CoV-2 and conduct treatment studies to advance high-priority therapeutic candidates.</p><p id="par0010">In this review we discuss investigational treatments (Supplementary <xref rid="tbl0005" ref-type="table">Table 1</xref>
), both repurposed and novel, early data regarding their use in the treatment of COVID-19, and key clinical trials that are currently under way (<xref rid="tbl0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Key clinical trials for COVID-19 treatments that are currently under way.</p></caption><alt-text id="at0005">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">ACTT <xref rid="bib0220" ref-type="bibr">[44]</xref></th><th align="left">Convalescent Plasma EAP <xref rid="bib0165" ref-type="bibr">[33]</xref></th><th align="left">CORIMUNO-TOCI <xref rid="bib0195" ref-type="bibr">[39]</xref></th><th align="left">Regeneron <xref rid="bib0200" ref-type="bibr">[40]</xref></th></tr></thead><tbody><tr><td align="left">Trial ID</td><td align="left">NCT04280705</td><td align="left">NCT0433860</td><td align="left">NCT0433180839</td><td align="left">NCT04315298</td></tr><tr><td align="left">Study agent</td><td align="left">Remdesivir (RDV)</td><td align="left">Convalescent plasma</td><td align="left">Tocilizumab</td><td align="left">Sarilumab</td></tr><tr><td align="left">Study location</td><td align="left">International</td><td align="left">USA</td><td align="left">France</td><td align="left">USA</td></tr><tr><td align="left">Study design</td><td align="left">Adaptive, double-blind, placebo RCT</td><td align="left">Open-label expanded access program</td><td align="left">Open-label RCT</td><td align="left">Adaptive, phase 2/3, randomized, double-blind, placebo-controlled</td></tr><tr><td align="left">Patients</td><td align="left">1063 randomized (1059 included in preliminary analysis)</td><td align="left">5000</td><td align="left">129</td><td align="left">457</td></tr><tr><td align="left">Median age, yr (range)</td><td align="left">58.9</td><td align="left">62.3 (18.5&#x02013;97.8)</td><td align="left">Not reported</td><td align="left">Not reported</td></tr><tr><td align="left">Male patients</td><td align="left">RDV: 352 (65.1%); Placebo: 332 (63.6%)</td><td align="left">3153 (63.1%)</td><td align="left">Not reported</td><td align="left">Not reported</td></tr><tr><td align="left">Disease status</td><td align="left">RDV: 352 (65.1%); Placebo: 332 (63.6%)</td><td align="left">Severe or life-threatening: 4051 (81%)<break/>High risk of disease progression: 949 (19%)</td><td align="left">Moderate or severe (number not reported)</td><td align="left">Severe: 28%<break/>Critical: 49%<break/>MOD: 23%</td></tr><tr><td align="left">Baseline clinical status</td><td align="left">127 (11.9%) RA; 421 (39.6%) supplemental oxygen; 197 (18.5%) NIV/HFNC; 272 (25.6%) MV/ECMO</td><td align="left">Total ICU admissions: 3316 (66%)<break/>Respiratory failure: 2912 (72%)<break/>MOD/failure: 745 (18.4%)<break/>Septic shock: 600 (14.8%)</td><td align="left">All patients required O<sub>2</sub> supplementation, but levels not specified</td><td align="left">Not reported</td></tr><tr><td align="left">Clinical improvement</td><td align="left">Median Time to recovery: RDV: 11 days; Placebo: 15 days (p &#x0003c; 0.001); Rate ratio for recovery 1.32 (95% CI 1.12-1.55)</td><td align="left">Not reported</td><td align="left">Significantly lower proportion of patients in tocilizumab arm met primary outcome (need for NIV or MV) at day 14</td><td align="left">All patients met primary endpoint (% change in CRP): &#x02212;21% placebo vs &#x02212;77% sarilumab 200 mg vs &#x02212;79% sarilumab 400 mg<break/>Clinical improvement (critical): 18 (41%) placebo vs 48 (51%) sarilumab 200 mg vs 52 (59%) sarilumab 400 mg</td></tr><tr><td align="left">Death</td><td align="left">Mortality at 14 days: RDV: 7.1% (95% CI, 5-9.9); Placebo: 11.9% (95% CI, 9.2-15.4)</td><td align="left">7-d mortality rate: 14.9%</td><td align="left">Significantly lower proportion of patients in tocilizumab arm met primary outcome (death) at day 14</td><td align="left">Critical: 12 (27%) placebo vs 34 (36%) sarilumab 200 mg vs 20 (23%) sarilumab 400 mg</td></tr><tr><td align="left">Serious adverse events</td><td align="left">RDV: 114 (21.1%); Placebo: 141 (27.0%); Most common SAEs - respiratory failure, hypotension, viral pneumonia, AKI</td><td align="left">4 h after transfusion: 36 (&#x0003c;1%) including transfusion-associated circulatory overload (7); transfusion-related acute lung injury (11); severe allergic transfusion reactions</td><td align="left">Not reported</td><td align="left">No new safety signals</td></tr><tr><td align="left">Limitations</td><td align="left">Complete statistical analysis needed to determine efficacy and safety</td><td align="left">No control group; study not designed to assess efficacy of convalescent plasma</td><td align="left">Press release with limited preliminary data; not peer-reviewed</td><td align="left">Press release with limited preliminary data; not peer-reviewed</td></tr></tbody></table><table-wrap-foot><fn><p>ACTT: Adaptive COVID-19 Treatment Trial AKI: Acute Kidney Injury CI: Confidence Interval EAP: Expanded access program ECMO: Extracorporeal membrane oxygenation HFNC: High-flow nasal cannula ICU: Intensive Care Unit MV: Mechanical Ventilation NIV: Non-invasive Ventilation RA: Room Air RCT: Randomized controlled trial RDV: Remdesivir SAE: Serious Adverse Event.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0010"><label>2</label><title>Antiviral therapy</title><sec id="sec0015"><label>2.1</label><title>Chloroquine and hydroxychloroquine</title><p id="par0015">Chloroquine and hydroxychloroquine are antimalarial agents with immunomodulatory properties that exhibit antiviral activity in vitro against SARS-CoV-2 <xref rid="bib0010" ref-type="bibr">[2]</xref>, <xref rid="bib0015" ref-type="bibr">[3]</xref>. Early series from China revealed earlier viral clearance, improved radiologic findings, and shortened disease course among patients diagnosed with COVID-19 when treated with chloroquine <xref rid="bib0020" ref-type="bibr">[4]</xref>. In a small study from France, hydroxychloroquine, which has a more tolerable safety profile <xref rid="bib0025" ref-type="bibr">[5]</xref>, reduced SARS-CoV-2 viral burden, although the clinical significance was unclear <xref rid="bib0030" ref-type="bibr">[6]</xref>. With these limited data, on March 28, 2020, the FDA issued an emergency use authorization of hydroxychloroquine for the treatment of COVID-19.</p><p id="par0020">Several subsequent studies have not shown a benefit with hydroxychloroquine <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>, <xref rid="bib0045" ref-type="bibr">[9]</xref>, <xref rid="bib0050" ref-type="bibr">[10]</xref> but rather a trend towards potential harm, including QTC prolongation <xref rid="bib0055" ref-type="bibr">[11]</xref>, <xref rid="bib0060" ref-type="bibr">[12]</xref>. An open-label RCT of 150 patients did not find a significantly higher probability of viral clearance in the hydroxychloroquine group, and the risk of adverse events was greater compared to standard of care <xref rid="bib0065" ref-type="bibr">[13]</xref>. The ORCHID trial (NCT04332991) is a multicenter, blinded RCT that aims to compare the effect of hydroxychloroquine versus placebo on clinical outcomes among adults hospitalized with COVID-19 <xref rid="bib0070" ref-type="bibr">[14]</xref>.</p></sec><sec id="sec0020"><label>2.2</label><title>Remdesivir</title><p id="par0025">Remdesivir is a novel broad-spectrum antiviral that disrupts viral replication by inhibiting the RNA polymerase of RNA viruses such as coronaviruses <xref rid="bib0075" ref-type="bibr">[15]</xref>, <xref rid="bib0080" ref-type="bibr">[16]</xref>. Remdesivir has demonstrated antiviral and clinical effects in animal model studies of SARS COV-1, MERS-COV <xref rid="bib0085" ref-type="bibr">[17]</xref>, <xref rid="bib0090" ref-type="bibr">[18]</xref>, and most recently against SARS COV-2 <xref rid="bib0095" ref-type="bibr">[19]</xref>.</p><p id="par0030">Early studies of remdesivir in COVID-19 have been inconclusive because of non-RCT designs and an inability to achieve target enrollment <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0105" ref-type="bibr">[21]</xref>. On February 21, 2020, the National Institutes of Health launched the Adaptive COVID-19 Treatment Trial (ACTT - NCT04280705), a double-blind randomized, placebo-controlled trial. After the study team released independent data safety monitoring board (DSMB) recommendations for early unblinding due to an interim analysis which demonstrated 31% faster time to recovery (primary endpoint) among patients who received remdesvir compared to placebo (p &#x0003c; 0.001) <xref rid="bib0110" ref-type="bibr">[22]</xref>, the US FDA issued an emergency use authorization (EUA) on 1 May 2020 for remdesivir for hospitalized patients with confirmed COVID-19 with SpO<sub>2</sub> 94% and eGFR &#x0003e; 30 ml/min <xref rid="bib0115" ref-type="bibr">[23]</xref>. After the EUA, a preliminary report of the ACTT results was published on 22 May 2020. Initial data suggest that compared to placebo, patients in the remdesivir arm had a shorter time to recovery (median 11 days vs 15 days, p &#x0003c; 0.001) and reduced mortality at 14 days (7.1% vs 11.9%). Patients with critical disease (requiring non-invasive or mechanical ventilation) appeared to have a lower recovery rate than those with less severe disease, however, it is important to note that follow-up data collection and analysis are not yet complete <xref rid="bib0220" ref-type="bibr">[44]</xref>. Additional Phase 3 clinical trials (NCT04292730, NCT0429899) to determine the safety and efficacy of remdesivir in the treatment of moderate and severe COVID-19 remain ongoing and plan to enroll over 7000 patients.</p></sec></sec><sec id="sec0025"><label>3</label><title>Immune-based therapy</title><sec id="sec0030"><label>3.1</label><title>Convalescent plasma</title><p id="par0035">Convalescent plasma (CP) contains antibodies directed against specific pathogens and is used for passive immunization in the treatment of infections. CP has been used since the 19th century in infectious disease outbreaks including diphtheria, influenza, and, more recently, SARS, MERS, and Ebola <xref rid="bib0120" ref-type="bibr">[24]</xref>, <xref rid="bib0125" ref-type="bibr">[25]</xref>, <xref rid="bib0130" ref-type="bibr">[26]</xref>, <xref rid="bib0135" ref-type="bibr">[27]</xref>, <xref rid="bib0140" ref-type="bibr">[28]</xref>. Some limited studies demonstrate a reduction in mortality, with the greatest benefit when CP is administered early in the disease course. However, there are no data that clearly demonstrate the value of CP for the treatment of any infectious disease <xref rid="bib0145" ref-type="bibr">[29]</xref>.</p><p id="par0040">While case series from early in the SARS-CoV-2 pandemic demonstrate a possible role for CP in COVID-19 <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0155" ref-type="bibr">[31]</xref>, <xref rid="bib0160" ref-type="bibr">[32]</xref>, no RCT data are available. As an investigational agent, CP is currently available via clinical trials, single-patient emergency use, or expanded access protocols (EAPs). On March 30, 2020, the FDA identified the Mayo Clinic as sponsor of the national EAP. In a preprint publication of the first safety EAP study communications, CP was found to be safe among 5000 recipients with no signal of toxicity beyond what is expected from plasma use in severely ill patients <xref rid="bib0165" ref-type="bibr">[33]</xref>. Ongoing RCTs are investigating the use of CP in hospitalized patients and in ambulatory settings and for post-exposure prophylaxis.</p></sec><sec id="sec0035"><label>3.2</label><title>IL-6 inhibitors</title><p id="par0045">Similar to the previous coronavirus, the systemic organ damage seen in COVID-19 is due to a &#x0201c;cytokine storm&#x0201d;, release of proinflammatory cytokines including IL-6 <xref rid="bib0075" ref-type="bibr">[15]</xref>, <xref rid="bib0170" ref-type="bibr">[34]</xref>, <xref rid="bib0175" ref-type="bibr">[35]</xref>. Tocilizumab, a monoclonal antibody that blocks the IL-6 receptor, is FDA approved for the treatment of cytokine release syndrome (CRS) <xref rid="bib0180" ref-type="bibr">[36]</xref>, <xref rid="bib0185" ref-type="bibr">[37]</xref>. An early retrospective report on 21 patients with severe or critical COVID-19 showed significant improvement in CRS symptoms, including resolution of fever and decreased oxygen requirements after treatment with tocilizumab <xref rid="bib0190" ref-type="bibr">[38]</xref>. Although case series were promising, recommendations included the need for RCTs.</p><p id="par0050">On April 27, 2020, a press release regarding the CORIMUNO-TOCI trial (NCT04331808), a multicenter, open-label RCT, noted significant improvement among patients with moderate or severe COVID-19 randomized to receive tocilizumab versus standard of care <xref rid="bib0195" ref-type="bibr">[39]</xref>. Sarilumab, another monoclonal antibody that blocks the IL-6 receptor, is currently being studied in a phase 2/3 adaptive, double-blind, placebo-controlled RCT (NCT04315298). After recommendations by an independent DSMB, a press release on April 27, 2020 announced that the study will only enroll patients with critical disease due to negative outcomes in other groups <xref rid="bib0200" ref-type="bibr">[40]</xref>. Results of both trials are still pending peer review. Additional clinical trials are under way for multiple immunomodulators in the treatment of COVID-19 and are not recommended outside of a clinical trial.</p></sec></sec><sec id="sec0040"><label>4</label><title>Discussion</title><p id="par0055">The recent epidemics of SARS-CoV-1, MERS-CoV, and Ebola highlight the importance of carrying out RCTs during a public health emergency. In those outbreaks, treatment decisions were made on the basis of observational reports and limited RCTs <xref rid="bib0205" ref-type="bibr">[41]</xref>. An immediate consequence of this approach is an incorrect assumption that investigative treatment is more likely to benefit than cause harm <xref rid="bib0210" ref-type="bibr">[42]</xref>. In the long term, lack of RCTs leads to insufficient answers regarding safe and effective treatment and risks, degrading public trust in health agencies <xref rid="bib0210" ref-type="bibr">[42]</xref>, <xref rid="bib0215" ref-type="bibr">[43]</xref>. The unprecedented speed with which numerous clinical trials have been initiated during the COVID-19 pandemic underscore the ability of the scientific community to provide this essential research.</p><p id="par0060">
&#x02028;&#x02028;
<bold><italic>Conflicts of interest:</italic></bold> The authors have nothing to disclose.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><mixed-citation publication-type="other" id="oref0005">National Institutes of Health. NIAID strategic plan for COVID-19 research. Published 22 April 22, 2020. www.niaid.nih.gov/sites/default/files/NIAID-COVID-19-Strategic-Plan-2020.pdf.</mixed-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><volume>30</volume><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C.</given-names></name><name><surname>Daher</surname><given-names>W.</given-names></name><name><surname>Chavain</surname><given-names>N.</given-names></name></person-group><article-title>Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities</article-title><source>J Med Chem</source><volume>49</volume><year>2006</year><fpage>2845</fpage><lpage>2849</lpage><pub-id pub-id-type="pmid">16640347</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci Trends</source><volume>14</volume><year>2020</year><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><mixed-citation publication-type="other" id="oref0025">Yao, X, Ye F., Zhang M., et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. In press. https://doi.org/10.1093/cid/ciaa237.</mixed-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name></person-group><article-title>Clinical and microbiological effect of a combination hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow-up: a pilot observational study</article-title><source>Travel Med Infect Dis</source><volume>34</volume><year>2020</year><object-id pub-id-type="publisher-id">101663</object-id></element-citation></ref><ref id="bib0035"><label>7</label><mixed-citation publication-type="other" id="oref0035">Magagnoli J., Narendran S., Pereira F., et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv preprint. https://doi.org/10.1101/2020.04.16.20065920.</mixed-citation></ref><ref id="bib0040"><label>8</label><mixed-citation publication-type="other" id="oref0040">Geleris J., Sun Y., Platt J., et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2012410.</mixed-citation></ref><ref id="bib0045"><label>9</label><mixed-citation publication-type="other" id="oref0045">Rosenberg E.S., Dufort E.M., Udo T., et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. In press. https://doi.org/10.1001/jama.2020.8630.</mixed-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Mahevas</surname><given-names>M.</given-names></name><name><surname>Tran</surname><given-names>V.T.</given-names></name><name><surname>Roumier</surname><given-names>M.</given-names></name></person-group><article-title>Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m1844</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1844</pub-id><pub-id pub-id-type="pmid">32409486</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><mixed-citation publication-type="other" id="oref0055">Mahevas M., Tran V.-T., Roumier M., et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv preprint. https://doi.org/10.1101/2020.04.10.20060699.</mixed-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>M.G.S.</given-names></name><name><surname>Val</surname><given-names>F.F.A.</given-names></name><name><surname>Sampaio</surname><given-names>V.S.</given-names></name></person-group><article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial</article-title><source>JAMA Netw Open</source><volume>3</volume><year>2020</year><object-id pub-id-type="publisher-id">e208857</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomized control trial</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m1849</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1849</pub-id><pub-id pub-id-type="pmid">32409561</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><mixed-citation publication-type="other" id="oref0070">ClinicalTrials.gov. Accessed May 15, 2020. https://clinicaltrials.gov.</mixed-citation></ref><ref id="bib0075"><label>15</label><mixed-citation publication-type="other" id="oref0075">Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. In press. https://doi.org/10.1001/jama.2020.6019.</mixed-citation></ref><ref id="bib0080"><label>16</label><mixed-citation publication-type="other" id="oref0080">Yin W., Mao C., Luan X., et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. In press. https://doi.org/10.1126/science.abc1560.</mixed-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Cronin</surname><given-names>J.</given-names></name></person-group><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><year>2020</year><fpage>6771</fpage><lpage>6776</lpage><pub-id pub-id-type="pmid">32054787</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name></person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci Transl Med</source><volume>9</volume><year>2017</year><comment>eaal3653</comment></element-citation></ref><ref id="bib0095"><label>19</label><mixed-citation publication-type="other" id="oref0095">Williamson B.N., Feldmann F., Schwarz B., et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv preprint. https://doi.org/10.1101.2020.04.15.043166.</mixed-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>J.</given-names></name><name><surname>Ohmagari</surname><given-names>N.</given-names></name><name><surname>Shin</surname><given-names>D.</given-names></name></person-group><article-title>Compassionate use of remdesivir for patients with severe Covid-19</article-title><source>N Engl J Med</source><volume>382</volume><issue>24</issue><year>2020</year><fpage>2327</fpage><lpage>2336</lpage><pub-id pub-id-type="pmid">32275812</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">32423584</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><mixed-citation publication-type="other" id="oref0110">National Institutes of Health. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19.</mixed-citation></ref><ref id="bib0115"><label>23</label><mixed-citation publication-type="other" id="oref0115">US Food and Drug Administration. Fact sheet for health care providers. Emergency use authorization (EUA) of remdesivir (GS-5734). www.fda.gov/media/137566/download.</mixed-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Dunmire</surname><given-names>G.B.</given-names></name></person-group><article-title>Some observations of treating cases of diphtheria</article-title><source>JAMA</source><volume>XXI</volume><year>1893</year><fpage>853</fpage><lpage>857</lpage></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>T.C.</given-names></name><name><surname>Kilbane</surname><given-names>E.M.</given-names></name><name><surname>Jackson</surname><given-names>J.L.</given-names></name><name><surname>Hoffman</surname><given-names>S.L.</given-names></name></person-group><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Ann Intern Med</source><volume>145</volume><year>2006</year><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">16940336</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J Infect Dis</source><volume>211</volume><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>I.F.N.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name></person-group><article-title>Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection</article-title><source>Chest</source><volume>144</volume><year>2013</year><fpage>464</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">23450336</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>van Griensven</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>T.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name></person-group><article-title>Evaluation of convalescent plasma for Ebola virus disease in Guinea</article-title><source>N Engl J Med</source><volume>374</volume><year>2016</year><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26735992</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><mixed-citation publication-type="other" id="oref0145">Rubin R. Testing an old therapy against a new disease: convalescent plasma for COVID-19. JAMA. In press. https://doi.org/10.1001/jama.2020.7456.</mixed-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name></person-group><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><mixed-citation publication-type="other" id="oref0155">Zeng Q.L., Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis. In press. https://doi.org/10.1093/infdis/jiaa228.</mixed-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><year>2020</year><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="bib0165"><label>33</label><mixed-citation publication-type="other" id="oref0165">Joyner M., Wright R.S., Fairweather D., et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. medRxiv preprint. https://doi.org/10.1101/2020.05.12.20099879.</mixed-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>K.J.</given-names></name><name><surname>Su</surname><given-names>I.J.</given-names></name><name><surname>Theron</surname><given-names>M.</given-names></name></person-group><article-title>An interferon-gamma-related cytokine storm in SARS patients</article-title><source>J Med Virol</source><volume>75</volume><year>2005</year><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15602737</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhan</surname><given-names>Y.</given-names></name></person-group><article-title>Analysis of serum cytokines in patients with severe acute respiratory syndrome</article-title><source>Infect Immun</source><volume>72</volume><year>2004</year><fpage>4410</fpage><lpage>4415</lpage><pub-id pub-id-type="pmid">15271897</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Teachey</surname><given-names>D.T.</given-names></name><name><surname>Rheingold</surname><given-names>S.R.</given-names></name><name><surname>Maude</surname><given-names>S.L.</given-names></name></person-group><article-title>Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorate with cytokine-directed therapy</article-title><source>Blood</source><volume>121</volume><year>2013</year><fpage>5154</fpage><lpage>5157</lpage><pub-id pub-id-type="pmid">23678006</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Le RQ</surname><given-names>Li L.</given-names></name><name><surname>Yuan</surname><given-names>W.</given-names></name></person-group><article-title>FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome</article-title><source>Oncologist</source><volume>23</volume><year>2018</year><fpage>943</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">29622697</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><year>2020</year><fpage>10970</fpage><lpage>10975</lpage><pub-id pub-id-type="pmid">32350134</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="book" id="sbref0195"><person-group person-group-type="author"><name><surname>Assistance Publique-H&#x000f4;pitaux de Paris</surname></name></person-group><chapter-title>Press release. Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. AP-HP; April 27</chapter-title><year>2020</year></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="book" id="sbref0200"><person-group person-group-type="author"><name><surname>Regeneron</surname></name></person-group><chapter-title>Press release. Regeneron and Sanofi provide update on U.S. Phase 2/3 adaptive-designed trial of KEVZARA (sarilumab) in hospitalized COVID-19 patients. Regeneron; April 27</chapter-title><year>2020</year></element-citation></ref><ref id="bib0205"><label>41</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>London</surname><given-names>A.J.</given-names></name><name><surname>Omotade</surname><given-names>O.O.</given-names></name><name><surname>Mello</surname><given-names>M.M.</given-names></name><name><surname>Keusch</surname><given-names>G.T.</given-names></name></person-group><article-title>Ethics of randomized trials in a public health emergency</article-title><source>PLoS Negl Trop Dis</source><volume>12</volume><year>2018</year><fpage>e0006313</fpage><pub-id pub-id-type="pmid">29771907</pub-id></element-citation></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Kalil</surname><given-names>A.C.</given-names></name></person-group><article-title>Treating COVID-19&#x02014;off-label drug use, compassionate use, and randomized clinical trials during pandemics</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1897</fpage><lpage>1898</lpage></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>J.L.</given-names></name><name><surname>Borio</surname><given-names>L.</given-names></name></person-group><article-title>Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1899</fpage><lpage>1900</lpage></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>J.H.</given-names></name><name><surname>Tomashek</surname><given-names>K.M.</given-names></name><name><surname>Dodd</surname><given-names>L.E.</given-names></name><name><surname>Mehta</surname><given-names>A.K.</given-names></name></person-group><article-title>Remdesivir for the Treatment of Covid-19 - Preliminary Report</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id><comment>In press</comment></element-citation></ref></ref-list><sec id="sec0050" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="par0070">The following are Supplementary data to this article:<supplementary-material content-type="local-data" id="upi0005"><media xlink:href="mmc1.docx"/></supplementary-material>
<supplementary-material content-type="local-data" id="upi0010"><media xlink:href="mmc2.docx"/></supplementary-material>
</p></sec><fn-group><fn id="sec0045" fn-type="supplementary-material"><label>Appendix A</label><p id="par0065">Supplementary material related to this article can be found, in the online version, at doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.euf.2020.05.019" id="intr0005">https://doi.org/10.1016/j.euf.2020.05.019</ext-link>.</p></fn></fn-group></back></article>